Advertisement
Screener

Oncotelic Therapeutics, Inc. (OTLC) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

2.8 / 5 stars · 68/120 Roast Me

Oncotelic Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

Oncotelic Therapeutics, Inc. (OTLC) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted of 1.42 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted · last filed 2026-08-13

  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2026-06-30 was 0.00 shares.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2026-03-31 was 1.42M shares.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2025-12-31 was 23.93M shares.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2024-12-31 was 0.00 shares, a 100.00% decline year-over-year.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2025 was 29.27M shares, a 763.57% increase from fiscal 2024.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2024 was 3.39M shares, a 85.37% decline from fiscal 2023.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2023 was 23.16M shares, a 40.02% decline from fiscal 2022.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2022 was 38.62M shares, a 11.59% increase from fiscal 2021.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 12 month
2026-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
1.42M shares
10-Q · filed 2026-08-13
25.35M shares
derived: sum of 3 quarters · filed 2026-08-13
2026-03-311.42M shares
10-Q · filed 2026-05-14
25.35M shares
derived: sum of 2 quarters · filed 2026-05-14
2025-12-3123.93M shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15
29.27M shares
10-K · filed 2026-04-15
2025-09-305.35M shares
10-Q · filed 2025-11-17
2024-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15
0.00 shares
derived: sum of 2 quarters · filed 2026-04-15
0.00 shares
derived: sum of 3 quarters · filed 2026-04-15
3.39M shares
10-K · filed 2026-04-15
2024-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17
0.00 shares
derived: sum of 2 quarters · filed 2025-11-17
3.39M shares
10-Q · filed 2025-11-17
15.26M shares
derived: sum of 4 quarters · filed 2025-11-17
2024-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13
3.39M shares
10-Q · filed 2025-08-13
15.26M shares
derived: sum of 3 quarters · filed 2025-08-13
2024-03-313.39M shares
10-Q · filed 2025-05-15
15.26M shares
derived: sum of 2 quarters · filed 2025-05-15
2023-12-3111.87M shares
derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15
23.16M shares
10-K · filed 2025-04-15
2023-09-3011.30M shares
10-Q · filed 2024-11-19
2022-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-12
4.25M shares
derived: sum of 2 quarters · filed 2024-04-12
5.62M shares
derived: sum of 3 quarters · filed 2024-04-12
38.62M shares
10-K · filed 2024-04-12
2022-09-304.25M shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
5.62M shares
derived: sum of 2 quarters · filed 2023-11-14
38.62M shares
10-Q · filed 2023-11-14
49.20M shares
derived: sum of 4 quarters · filed 2023-11-14
2022-06-301.38M shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-18
34.38M shares
10-Q · filed 2023-08-18
44.95M shares
derived: sum of 3 quarters · filed 2023-08-18
44.95M shares
derived: sum of 4 quarters · filed 2023-08-18
2022-03-3133.00M shares
10-Q · filed 2023-05-22
43.58M shares
derived: sum of 2 quarters · filed 2023-05-22
43.58M shares
derived: sum of 3 quarters · filed 2023-05-22
65.58M shares
derived: sum of 4 quarters · filed 2023-05-22
2021-12-3110.58M shares
derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-20
10.58M shares
derived: sum of 2 quarters · filed 2023-04-20
32.58M shares
derived: sum of 3 quarters · filed 2023-04-20
34.61M shares
10-K/A · filed 2023-04-20
2021-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-22
22.00M shares
derived: sum of 2 quarters · filed 2021-11-22
24.04M shares
10-Q · filed 2021-11-22
24.59M shares
derived: sum of 4 quarters · filed 2022-04-15
2021-06-3022.00M shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-20
24.04M shares
10-Q · filed 2021-08-20
24.59M shares
derived: sum of 3 quarters · filed 2022-04-15
27.50M shares
derived: sum of 4 quarters · filed 2022-04-15
2021-03-312.04M shares
10-Q · filed 2021-05-24
2.58M shares
derived: sum of 2 quarters · filed 2022-04-15
5.50M shares
derived: sum of 3 quarters · filed 2022-04-15
5.50M shares
derived: sum of 4 quarters · filed 2022-04-15
2020-12-31550.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-15
3.46M shares
derived: sum of 2 quarters · filed 2022-04-15
3.46M shares
derived: sum of 3 quarters · filed 2022-04-15
17.21M shares
10-K · filed 2022-04-15
2020-09-302.92M shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16
2.92M shares
derived: sum of 2 quarters · filed 2020-11-16
16.66M shares
10-Q · filed 2020-11-16
2020-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14
13.75M shares
10-Q · filed 2020-08-14
2020-03-3113.75M shares
10-Q · filed 2020-06-29
2018-12-3116.36M shares
10-K · filed 2020-05-14